Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 22.1% in November

Revance Therapeutics, Inc. (NASDAQ:RVNC) was the recipient of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 12,210,000 shares, a growth of 22.1% from the October 31st total of 10,000,000 shares. Based on an average daily trading volume, of 3,050,000 shares, the short-interest ratio is presently 4.0 days.

Wall Street Analyst Weigh In

RVNC has been the subject of several recent research reports. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Barclays reiterated an “equal weight” rating and issued a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Finally, StockNews.com started coverage on Revance Therapeutics in a research report on Tuesday, November 26th. They set a “hold” rating on the stock. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Revance Therapeutics has an average rating of “Hold” and an average price target of $9.66.

Institutional Investors Weigh In On Revance Therapeutics

Large investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Revance Therapeutics in the 3rd quarter worth approximately $120,000. Wellington Management Group LLP bought a new stake in Revance Therapeutics during the third quarter worth approximately $2,315,000. State Street Corp lifted its position in Revance Therapeutics by 6.6% in the third quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock worth $12,632,000 after purchasing an additional 150,323 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Revance Therapeutics by 11.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 265,210 shares of the biopharmaceutical company’s stock worth $1,376,000 after purchasing an additional 27,420 shares during the period. Finally, FORA Capital LLC bought a new position in Revance Therapeutics during the 3rd quarter valued at $54,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Trading Down 4.5 %

NASDAQ RVNC traded down $0.17 on Friday, hitting $3.61. 1,896,957 shares of the stock traded hands, compared to its average volume of 2,530,491. The company has a market capitalization of $378.69 million, a P/E ratio of -1.87 and a beta of 0.95. The stock has a 50-day moving average of $4.92 and a 200 day moving average of $4.44. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. As a group, equities research analysts expect that Revance Therapeutics will post -1.54 earnings per share for the current year.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.